Video & Transcript : 'pharmaceutical compounding' :

Page 1 of 170
WA

Washington 2025-2026 Regular Session

House Health Care & Wellness Jan 30th, 2026 at 08:00 am

Health Care & Wellness

Transcript Highlights:
  • As a pharmacist, compounding is the joy. on compounded drugs.
  • compounded drug.
  • This compounding is being fueled by the high-volume importation of active pharmaceutical ingredients,
  • This compounding is being fueled by the high-volume importation of active pharmaceutical ingredients,
  • pharmaceutical industry here in Washington State, creating a compounding pharmacy desert.
US
Transcript Highlights:
  • In my view, we need an NIH director who is prepared to... take on the greed of the pharmaceutical industry
Summary: The meeting focused on vital health-related nominations, primarily emphasizing the roles of Dr. Jay Bhattacharya for NIH Director and Dr. Monty McCary for FDA Commissioner. During the discussion, various senators expressed their support and concerns regarding these nominations. Senator Sanders voiced opposition to both candidates, highlighting issues related to drug affordability and public trust in health agencies. He emphasized the need for leaders committed to transparency and addressing the epidemic of high prescription drug prices, advocating for action against pharmaceutical industry greed. Overall, the conversation underscored the critical crossroads in public health leadership amidst ongoing challenges such as trust restoration and healthcare accessibility.
AZ

Arizona 2026 Regular Session

02/18/2026 - House International Trade

International Trade

Transcript Highlights:
  • But it doesn't prevent compounding; compounding can still occur if these checks are met. Mr.
  • First, the FDA does not approve or disapprove compounded medications or active pharmaceutical ingredients
  • How many GLP-1 doses are you compounding? How many GLP-1 are we compounding?
  • We do compound some GLP-1.
  • used in compounding.
US
Transcript Highlights:
  • information sharing between the FDA and the Patent Office for joint work on patent matters, including pharmaceutical
  • One of the reasons is that big pharmaceutical companies, big pharma, are able to game the patent system
  • But pharmaceutical companies abuse and manipulate the patent system to block generics from coming to
  • I think we all know that generics biosimilars have to be safe, but for too long the pharmaceutical companies
  • But when you put it on their net revenue, You compound the problem that I'm trying to address through
Summary: The meeting focused on addressing the high cost of prescription drugs and the abusive practices that contribute to elevated prices affecting American families. Several bills were presented, including proposals to end pay-for-delay deals and to enhance transparency in the operations of pharmacy benefit managers (PBMs). The discussion was notable for its emphasis on consumer protection and ensuring that cheaper generic drugs reach the market more effectively. Members expressed frustration over past attempts to pass similar legislation stalling in the Senate, leading to renewed efforts to push these bills forward.
MN

Minnesota 2025-2026 Regular Session

House Health Finance and Policy Committee 3/9/26

Health Finance and Policy

Transcript Highlights:
  • We cannot wait for an FDA-approved pharmaceutical version of a treatment that readily exists in nature
  • So only compounding pharmacies could add flavor to medication now.
  • of pharmaceutical products.
  • Compounding refers to creating a pharmaceutical or changing a conventionally manufactured product.
  • Compounding pharmacists can flavor medicines if certain conditions are met.
MA

Massachusetts 2025-2026 Regular Session

Joint Committee on Consumer Protection and Professional Licensure Jun 23rd, 2026

Joint Committee on Consumer Protection and Professional Licensure

Bills: S3082, S3090, H5425, H5130, H5114
Summary: The Joint Committee on Consumer Protection and Professional Licensure held a hearing on late-filed bills, with testimony heard both in person and remotely. The committee reviewed several measures, including H. 355 and S. 3082 on veterinary telemedicine/telehealth, H. 5445 on additional liquor licenses for East Hampton, and S. 3090/H. 5114 on consumer-connected devices and software support disclosure. The chair outlined hearing logistics, including three-minute testimony limits and written testimony submission, and noted that Lawrence High School students were present to observe. On the veterinary bills, supporters of H. 355 argued that allowing veterinarians to establish a client-patient relationship remotely would improve access to care for pets whose owners face transportation, mobility, or anxiety-related barriers, and could help veterinarians continue practicing through telemedicine. Opponents of S. 3082, including the Massachusetts Veterinary Medical Association and several veterinarians, said the initial in-person exam is essential to detect conditions that cannot be seen on video, avoid misdiagnosis, and preserve the standard of care; they emphasized that teletriage and follow-up telemedicine are already used after an in-person relationship is established. Committee members pressed both sides on the distinction between teletriage and establishing the relationship, the timing of annual exams, and whether limited exceptions for sedatives or other pre-visit needs might be workable. Senator Lovely testified in support, citing a recent Lyme case where follow-up telemedicine would have been useful. On H. 5445, Representative Gomez and East Hampton Mayor Salem Derby urged approval of the bill to authorize eight additional liquor licenses, saying the city has reached its current cap, needs economic development, and wants to support downtown revitalization and new restaurant growth. Members asked about public safety and the number of licenses sought; the mayor said local public safety officials support the request and that the licenses would be for restaurants, not bars. On S. 3090 and H. 5114, consumer advocates and cybersecurity experts supported requiring manufacturers of connected devices to disclose software support timelines, arguing it would improve consumer transparency, cybersecurity, and reduce e-waste. Industry groups opposed the bills, saying fixed disclosure requirements could be impractical, create confusion, burden small businesses, conflict with federal efforts, and be difficult to apply to appliances, lighting, and other products with long lifecycles. The committee did not take a substantive vote on the bills during the hearing; at the end, staff announced a forthcoming poll for House members, and the committee voted to adjourn.
TX
Transcript Highlights:
  • someone's belly before a meal would try and weaponize the very suffering that you inflict as a means to compound
  • Senate Bill 6 would compound trauma, erode privacy, and weaponize the legal system. ...against those
Bills: SB10, SB16, SB6, SB 6, SB 10, SB 16
HI

Hawaii 2026 Regular Session

HSH Public Hearing - Thu Feb 12, 2026 @ 10:30 AM HST

Human Services & Homelessness

Transcript Highlights:
  • which is relating to Medicaid, HB 2224, which basically gives Medicaid more flexibility around pharmaceutical
  • Medicaid more flexibility<00:42:58.640><c> around</c><00:42:59.680><c> um</c><00:42:59.920><c> pharmaceutical
  • </c> flexibility around um pharmaceutical flexibility around um pharmaceutical benefits<00:43:01.760>
  • 00:46:38.800><c> of</c> keeping trying to keep the cost of keeping trying to keep the cost of pharmaceuticals
  • as low as possible for pharmaceuticals as low as possible for beneficiaries,<00:46:42.560><c> but</c
Summary: The committee heard testimony on HB 1877, which would expand the membership of the Hawaii State LGBTQ+ Commission and add a youth seat. The commission’s vice chair supported the bill, saying the commission started with eight members, has growing interest, and would benefit from an odd-numbered board and youth representation. Members asked about quorum, and the commission said it has generally met monthly with only one quorum issue in the past 18–19 months and would work with legislative leaders to have appointments ready if the bill passes. Written testimony included support from Kokopac and one individual in opposition. The committee then took up HB 2006, which would create a cash assistance program for pregnant women and mothers of babies. The Department of Human Services explained current TANF rules, including eligibility requirements, child support cooperation, and work-program participation, and said the state has recently raised benefit levels to the maximum allowed, with a family of three or four receiving a little over $900 per month. Supporters from the Hawaii Public Health Institute, Hawaii Children’s Action Network Speaks, and others argued the bill could reduce child poverty and improve maternal and child health, citing evidence from Michigan’s Rx Kids program and the temporary federal child tax credit expansion. A mother and Oahu Youth Action Board member testified from personal experience about the need for direct support during pregnancy. The committee also noted support from several organizations and about 26 individuals. The committee next heard HB 2167, which would direct the Office of Youth Services to run a pilot program providing financial assistance to homeless youth. The Office of the Public Defender, youth advocates, and several organizations supported the measure, saying even small amounts of help can prevent homelessness and help youth transition safely to adulthood. The Office of Youth Services said it supports the intent of the bill but requested clarification, and committee members discussed whether the program should be run directly or through contracted community agencies, how to set performance metrics, and how to structure the RFP and contract process. The chair indicated the committee wanted to work with the vice chair and OYS offline to refine the bill before moving forward. The committee then began discussion of HB 2224, relating to Medicaid pharmacy benefit management, with testimony generally supporting giving DHS flexibility to negotiate with PBMs.
OK
Summary: The House reconvened after a quorum call and took up several Senate bills with joint committee reports, mostly involving health and human services funding. SB 1130, relating to University Hospitals authority, passed 74-12 and its emergency clause also passed. SB 1134, funding the Oklahoma State University Medical Authority, passed 75-14 with the emergency clause approved. SB 1131, appropriating ARP interest funds to address a Rogers County gap for the Office of Juvenile Affairs, passed 81-10 and the emergency clause passed. SB 1132, reappropriating ARPA funds for rural hospital rebuild programs under the State Department of Health to avoid federal clawback, passed 82-10 with emergency approval. SB 1133, involving the Department of Mental Health and Substance Abuse Services and repurposing interest funds for a Norman building project, passed 68-24 and its emergency clause also passed. SB 1142, appropriating ARPA funds to the Department of Human Services consistent with pandemic relief recommendations, passed 68-21 and the emergency clause was adopted. The House also considered H.R. 1049, a resolution designating May as Asthma and Allergy Awareness Month. Representative Newton summarized asthma’s impact in Oklahoma and nationally, including child health effects and recent deaths in the state, and moved adoption by unanimous consent. The transcript ends with announcements and adjournment until the next scheduled meeting.
OK
Summary: The House convened, called the roll, and opened with prayer, the Pledge of Allegiance, and a series of recognitions and presentations. Members honored Vice Admiral Jeff Trusler as Veteran of the Week, recognized the Prague Kolache Festival royalty and candidates, unveiled an artwork for the Capitol’s Hall of Heroes, and introduced the Doctor, Psychologist, and Nurse of the Day, along with the OSBI cold case team. The House also adopted HCR 1026, a resolution tied to Earth Day and “Lights Out Day” in Oklahoma, aimed at reducing light pollution and protecting migrating birds. A major portion of the meeting consisted of farewell remarks from Representatives Mike Osborne and Kevin West. Both reflected on their years of service, thanked family, staff, colleagues, and constituents, and emphasized themes of public service, hard work, conviction, and working across differences. Osborne’s remarks focused on freedom, immigration, service, and doing good in public life, while West stressed standing on principle, listening to others, and choosing courage over convenience. After the presentations and personal privilege speeches, the House moved into consideration of legislation. Chairman Caldwell presented the joint committee report on Senate Bill 1130, relating to the University Hospitals Authority, saying it would help ensure Oklahoma and the University of Oklahoma have one of the world’s leading pediatric cardiology units. The transcript ends as members begin considering the bill, with no final vote shown in the excerpt.
MA
Transcript Highlights:
  • I don't know if we'll touch on this, but pharmaceutical-grade xylazine versus non-pharmaceutical-grade
  • compounds that you would attain from a pharmacy or from a pharmaceutical distributor or a compounding
  • The non-PG, as we call non-pharmaceutical-grade compounds.
  • compounds can easily go missing.
  • Hogan, you called it a cousin compounds. Yeah, that's not proper. Compounds.
Keywords: 995, all
Summary: The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches. Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice. The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.
OK

Oklahoma 2026 Regular Session

Joint Committee on Appropriations and Budget 2nd Revised Apr 20th, 2026 at 04:30 pm

Joint Committee on Appropriations and Budget

Transcript Highlights:
  • to address gaps in the human performance projects and up to $14 million to address gaps in the pharmaceutical
  • On page two, it looks like we have new funding of $14 million to Ouma on the pharmaceutical expansion
  • Again, yeah, this was the pharmaceutical program that they've had in place.